Spyre Therapeutics's total assets for Q4 2024 were $608.48M, an increase of 44.50% from the previous quarter. SYRE total liabilities were $90.68M for the fiscal quarter, a -3.22% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.